Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Cosette M Wheeler; S Rachel Skinner; M Rowena Del Rosario-Raymundo; Suzanne M Garland; Archana Chatterjee; Eduardo Lazcano-Ponce; Jorge Salmeron; Shelly McNeil; Jack T Stapleton; Celine Bouchard; Mark G Martens; Deborah M Money; Swee Chong Quek; Barbara Romanowski; Carlos S Vallejos; Bram ter Harmsel; Vera Prilepskaya; Kah Leng Fong; Henry Kitchener; Galina Minkina; Yong Kuei Timothy Lim; Tanya Stoney; Nahida Chakhtoura; Margaret E Cruickshank; Alevtina Savicheva; Daniel Pereira da Silva; Murdo Ferguson; Anco C Molijn; Wim GV Quint; Karin Hardt; Dominique Descamps; Pemmaraju V Suryakiran; Naveen Karkada; Brecht Geeraerts; Gary Dubin; Frank Struyf

Journal article

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Cosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, Suzanne M Garland, Archana Chatterjee, Eduardo Lazcano-Ponce, Jorge Salmeron, Shelly McNeil, Jack T Stapleton, Celine Bouchard, Mark G Martens, Deborah M Money, Swee Chong Quek, Barbara Romanowski, Carlos S Vallejos, Bram ter Harmsel, Vera Prilepskaya, Kah Leng Fong, Henry Kitchener, Galina Minkina Show all

The Lancet Infectious Diseases | ELSEVIER SCI LTD | Published : 2016

DOI: 10.1016/S1473-3099(16)30120-7

University of Melbourne Researchers

Suzanne Garland Wark Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Grants

Funding Acknowledgements

The VIVIANE study was funded and coordinated by GlaxoSmithKline Biologicals SA, which also covered all costs associated with development and publication of this report. We thank all study participants and their families. We gratefully acknowledge the work of the central and local study coordinators, and staff members of the sites who participated in this study. Writing support services were provided by Mary Greenacre (An Sgriobhadair, Isle of Barra, UK), on behalf of GSK Vaccines; editing and publication coordination services were provided by Jerome Leemans (Keyrus Biopharma, Lasne, Belgium), Stephanie Delval (XPE Pharma and Science, Wavre, Belgium), and Matthieu Depuydt (Business Decision Life Sciences, Brussels, Belgium), on behalf of GSK Vaccines.